Veracyte VCYT 深 沪
已收盘 08-01 16:00:00 美东时间
23.64
+0.130
+0.55%
华盛通- 最 高23.68
- 今 开23.25
- 成交量 174.16万股
- 最 低 22.92
- 昨 收 23.51
- 总市值 18.51亿
- 52周最高 47.3162
- 市盈率 静 76.55
- 换手率 2.22%
- 52周最低 22.61
- 委 比 67.22%
- 总股本 7831.46万
- 历史最高 86.03
- 量 比 0.33
- 振 幅 3.23%
- 历史最低 4.21
- 每 手 1
- 风险率 6.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BMNR, VCYT, ZG: Cathie Wood Buys $15M More of Ethereum-Linked Bitmine
Cathie Wood’s ARK InvestETFs(exchange-traded funds) poured millions...
07-30 14:55
Veracyte To Replace Triumph Group In The S&P Smallcap 600 Effective Prior To The Opening Of Trading On Tuesday, July 29
https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20250724-1478929/1478929_tgi6.pdf
07-25 05:17
Cathie Wood's Ark Invest Adds Airbnb, AMD, Shopify To Portfolio, Slashes Stake In Circle Internet
On Friday, Cathie Wood-led Ark Invest made significant trades, with a particula...
06-21 12:19
Cathie Wood's Ark Invest Loads Up On Veracyte, Offloads 3D Systems
Ark Invest made notable trades on Friday, including purchasing shares of Veracyte Inc. and selling shares of 3D Systems Corp.
06-07 13:24
Cathie Wood Dumps Another $5.2 Million Of Palantir Stock Amid Trump Administration-Linked Surveillance Controversy
On Wednesday, Cathie Wood's Ark Invest sold 40,035 shares of Palantir Technologies Inc, amidst controversy. They bought shares of Guardant Health Inc and Veracyte Inc.
06-05 09:23
Veracyte To Present Eight Abstracts Featuring Data Derived From Testing With Decipher Prostate And Decipher Bladder Genomic Classifiers At 2025 ASCO Annual Meeting
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that eight abstracts featuring data derived from testing with its Decipher Prostate and Decipher Bladder genomic classifiers will be
05-29 04:13
美股大行评级 | 潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
05-10 10:00
Needham Maintains Buy on Veracyte, Lowers Price Target to $41
Needham analyst Mike Matson maintains Veracyte (NASDAQ:VCYT) with a Buy and lowers the price target from $51 to $41.
05-08 18:42
Veracyte Q1 Adj. EPS $0.31 Beats $0.07 Estimate, Sales $114.47M Beat $110.86M Estimate
Veracyte (NASDAQ:VCYT) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.07 by 342.86 percent. This is a 63.16 percent increase over earnings of $0.19 per share from the same
05-08 04:09
Earnings Scheduled For May 7, 2025
Companies Reporting Before The Bell • Wallbox (NYSE:WBX) is estimated to report...
05-07 16:33
